Xpert® C. difficile/Epi
Detection of Clostridium difficileinfection with an independent call-out of the 027 strain in around 45 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Collection devices
product image
Collection Device (Pack of 50)
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

  • Clostridioides difficile infection (CDI) accounts for 15–25% of healthcare-associated diarrhea cases in all healthcare settings1
  • It is associated with an increase in length of hospital stay, high morbidity and mortality resulting in both societal and financial burden2
  • Although the accurate and rapid diagnosis of CDI is essential for effective and timely treatment, this remains an unmet clinical need4
1 Lessa FC, Winston LG, McDonald LC, Emerging Infections Program C. difficile Surveillance Team Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:2369–2370.
2 Tschudin-Sutter S, et al. Guidance document for prevention of C. difficile infection in acute healthcare settings. Clin Microbiol Infect 2018;24:1051
4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.

The Solution

  • The Xpert C. difficile/Epi test provides detection and differentiation of Clostridioides difficile & the epidemic 027strain, in 43 minutes from unformed stool specimens
  • Rapid detection and differentiation of Clostridioides difficile (CDI) & the epidemic 027 strain optimizes patient management decisions and supports infection control and outbreak prevention measures

The Impact

Rapid and accurate detection of toxigenic C. difficile is essential to diagnose CDI to implement optimized therapy and bed management and to help prevent transmission and outbreaks:
45% reduced empiric therapy5
48% reduced isolation days6
3 Markovska, R et al. Clostridioides difficile, a new suberbug, Microorganisms 2023, 11, 845. https://doi.org/10.3390/microorganisms11040845
5 Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):639-43.
6 Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40)